search

Active clinical trials for "Esophageal Squamous Cell Carcinoma"

Results 361-370 of 419

Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal...

Esophageal Squamous Cell CancerElderly Patients

Elderly patients with metastatic esophageal squamous cell carcinomas have poor prognosis and majority of them were intolerable to combined chemotherapy in China. In the investigators phase II clinical trial proceeded before, the paclitaxel treatment showed good tolerance and efficacy to esophageal squamous cell carcinomas. Radiotherapy has been indicated as a definitive treatment for unresectable or medically inoperable tumors in ESCC patients. However, not only the combination with chemotherapy, but also the boundaries of the clinical target volume (CTV) are not internationally defined. The investigators then initiated a prospective phase II clinical trial with sequential paclitaxel/cisplatin and radiotherapy as the 1st line treatment in elderly metastatic esophageal carcinoma to observe the efficacy and safety of the combination.

Unknown status18 enrollment criteria

A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous...

Esophageal Cancer

This is a multicenter, randomized, open-label, phase III trail comparing adjuvant chemoradiotherapy (Paclitaxel and carboplatin) to adjuvant radiotherapy in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal squamous cell carcinoma.

Unknown status15 enrollment criteria

Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer

Esophageal CancerChemoradiation1 more

The investigators designed a new preoperative chemoradiotherapy regimen to focus on the most important radiation area and hope to reduce the radiation volume and try to reduce the postoperative mortality and treatment-related mortality.

Unknown status13 enrollment criteria

Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard...

Esophageal Squamous Cell Carcinoma

We conduct the clinical trial to further explore the efficacy and safety of Apatinib combined with chemotherapy in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.

Unknown status24 enrollment criteria

Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma

Esophagus Squamous Cell Carcinoma (SCC)Metastatic Cancer

Esophageal or esophageal-gastric junction squamous cell cancer has dismal prognosis. And still no promising chemotherapeutic drugs is existed. In this study, The investigators wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the participants with inoperable or metastatic esophageal squamous cell carcinoma.

Unknown status37 enrollment criteria

Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma...

Esophageal Squamous Cell Carcinoma

This is an open-label phase II trial investigating the effect of metformin in combined with cisplatin plus paclitaxel as neoadjuvant therapy with advanced esophageal squamous cell carcinoma.

Unknown status25 enrollment criteria

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced...

Esophageal Squamous Cell Carcinoma

To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the treatment of advanced esophageal squamous cell carcinoma.

Unknown status34 enrollment criteria

Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

This is a single arm phase II study, in which 2 cycles of chemotherapy (5FU/CDDP) and immunotherapy (durvalumab and tremelimumab) are administered every 3 weeks with concurrent radiotherapy for inoperable locally advanced esophageal squamous cell carcinoma. Four weeks after completion of CCRT combined with immunotherapy, 2 cycles of durvaluma and tremelimumab will be administered every 4 weeks and thereafter durvalumab monotherapy Q4W will be maintained until unacceptable toxicity or disease progression, or for maximum 2 years after enrollment.

Unknown status6 enrollment criteria

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).

Unknown status19 enrollment criteria

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell...

Esophageal Squamous Cell CarcinomaProgression to PD-1 Antibody

This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.

Unknown status10 enrollment criteria
1...363738...42

Need Help? Contact our team!


We'll reach out to this number within 24 hrs